Samsung Life Science Fund is investing $10 million in a company developing technology for Alzheimer’s disease diagnostics.
Samsung C&T announced on the 13th that it will invest $10 million (approximately KRW 14.5 billion) in C2N Diagnostics (hereinafter C2N) through its Life Science Fund, which was established in collaboration with its subsidiaries Samsung Biologics, Samsung Bioepis, and Samsung Venture Investment.
C2N specializes in advanced technology that precisely measures and analyzes trace amounts of protein biomarkers in the blood. Leveraging this technology, the company has developed a blood test for diagnosing Alzheimer’s disease and has participated in clinical trials for Alzheimer’s treatments, as well as various central nervous system disease studies worldwide, demonstrating its technological capabilities.
C2N’s Alzheimer’s blood test is a cost-effective alternative to traditional diagnostic methods such as amyloid PET-CT (positron emission tomography) scans and cerebrospinal fluid (CSF) tests. The company claims that its test can safely and accurately measure key proteins related to Alzheimer’s, such as amyloid beta.
If such blood tests partially replace conventional diagnostic methods, including cognitive assessments, MRI scans, and CSF tests, they could provide a more accessible and convenient option for a broader population, according to C2N. The company plans to submit a regulatory approval application to the U.S. Food and Drug Administration (FDA) within this year for its Alzheimer’s blood test.
Jae-Woo Kim, Executive Vice President of Life Science Business at Samsung C&T, stated, “C2N is a highly promising company with strong potential to become a leading player in R&D support, contract services, and related fields. Through this fund investment, Samsung C&T has secured a strategic foothold in this sector.”
Joel Braunstein, CEO of C2N, commented, “This investment will allow us to further strengthen our technological capabilities, recruit top talent, and expand our services not only across the U.S. but also internationally.”
The Samsung Life Science Fund, managed by Samsung Venture Investment, is a KRW 240 billion venture investment fund jointly financed by Samsung C&T, Samsung Biologics, and Samsung Bioepis. The fund focuses on fostering next-generation biotech innovations and improving quality of life, having previously invested in companies such as Araris Biotech and Aimed Bio (specializing in next-generation ADCs) and Generate Biomedicines, which develops protein-based biologics using generative machine learning.
